A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.

A drug delivery device with removable pods is described and related pods methods and systems. The drug delivery device comprises a plurality of receptacles, each receptacle configured to accept a corresponding drug pod, wherein each receptacle comprises: a recess configured to accept a protrusion in the corresponding drug pod, or a protrusion configured to insert in a recess in the corresponding drug pod. The corresponding drug pod comprises a shell, made of an impermeable polymer, having a first base comprising an opening configured to allow delivery of a drug, a second base, a lateral surface, a protrusion attached to, and extending away from, the lateral surface, or a recess in the lateral surface.

A drug delivery device with removable pods is described and related pods methods and systems. The drug delivery device comprises a plurality of receptacles, each receptacle configured to accept a corresponding drug pod, wherein each receptacle comprises: a recess configured to accept a protrusion in the corresponding drug pod, or a protrusion configured to insert in a recess in the corresponding drug pod. The corresponding drug pod comprises a shell, made of an impermeable polymer, having a first base comprising an opening configured to allow delivery of a drug, a second base, a lateral surface, a protrusion attached to, and extending away from, the lateral surface, or a recess in the lateral surface.

A pharmaceutical composition for a sustained release of peptide therapeutics, in particular for a sustained release compatible with therapeutic treatments of at least two months. In an embodiment, the composition comprises lanreotide as an active agent, a hydrosoluble co-solvent, and water with the pH of the composition being from 4.0 to 7.5.

The present invention provides growth factor-directed agents (GDAs), which act as either antagonists or agonists of cell signaling, particularly in the TGF-beta and related extracellular matrix signaling pathways. Such GDAs include monoclonal antibodies, fusion proteins and novel polypeptide compositions and/or conjugates of these compositions.

Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs:

R.sup.1-A.sup.1-A.sup.2-A.sup.3-A.sup.4-A.sup.5-R.sup.2(I)

wherein:

A.sup.1 is Aib, Apc or Inp;

A.sup.2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp;

A.sup.3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp;

A.sup.4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl);

A.sup.5 is Apc, Dab, Dap, Lys, Orn, or deleted;

R.sup.1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and

R.sup.2 is OH or NH.sub.2;

and pharmaceutical compositions and methods of use thereof.

A pharmaceutical composition comprises octreotide acetate microparticles of linear poly (lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane.

Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent.

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).